Related Experiment Videos
A pharmacophore model for NK2 antagonist comprising compounds from several structurally diverse classes
Anders Poulsen1, Tommy Liljefors, Klaus Gundertofte
1Department of Medicinal Chemistry, The Royal Danish School of Pharmacy, Copenhagen, Denmark.
Journal of Computer-Aided Molecular Design
|October 29, 2002
Summary
A novel neurokinin 2 (NK2) antagonist pharmacophore model was developed and validated. This model accurately describes NK2 antagonists, aiding in the design of new therapeutic agents.
Area of Science:
- Medicinal Chemistry
- Computational Chemistry
- Pharmacology
Background:
- Neurokinin 2 (NK2) receptor antagonists are targets for various therapeutic applications.
- Developing accurate pharmacophore models is crucial for structure-based drug design.
Purpose of the Study:
- To develop and validate a pharmacophore model for neurokinin 2 (NK2) antagonists.
- To understand the key structural features required for NK2 antagonist binding.
Main Methods:
- Development of a pharmacophore model using five non-peptide NK2 antagonists.
- Validation of the model with 20 additional antagonists.
- Utilized conformational analysis (MMFFs, GB/SA hydration) and molecular superimposition.
Main Results:
- A pharmacophore model comprising three hydrophobic groups and a hydrogen bond donor vector was established.
- 23 out of 25 antagonists successfully fitted the model with low energy and RMS values.
- The model explained the enantioselectivity observed for specific antagonists (SR48968, GR159897).
Conclusions:
- The developed NK2 antagonist pharmacophore model is robust and predictive.
- The model highlights the importance of specific hydrophobic interactions and hydrogen bonding in antagonist binding.
- This model can guide the design of novel and potent NK2 receptor antagonists.